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Deletion of the Chemokine Binding
Protein Gene from the Parapoxvirus
Orf Virus Reduces Virulence and
Pathogenesis in Sheep
Stephen B. Fleming*, Catherine McCaughan, Zabeen Lateef, Amy Dunn, Lyn M. Wise,
Nicola C. Real and Andrew A. Mercer
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
Orf virus (ORFV) is the type species of the Parapoxvirus genus of the family Poxviridae
and infects sheep and goats, often around the mouth, resulting in acute pustular skin
lesions. ORFV encodes several secreted immunomodulators including a broad-spectrum
chemokine binding protein (CBP). Chemokines are a large family of secreted chemotactic
proteins that activate and regulate inflammation induced leukocyte recruitment to sites
of infection. In this study we investigated the role of CBP in vivo in the context of ORFV
infection of sheep. The CBP gene was deleted from ORFV strain NZ7 and infections
of sheep used to investigate the effect of CBP on pathogenesis. Animals were either
infected with the wild type (wt) virus, CBP-knockout virus or revertant strains. Sheep
were infected by scarification on the wool-less area of the hind legs at various doses of
virus. The deletion of the CBP gene severely attenuated the virus, as only few papules
formed when animals were infected with the CBP-knock-out virus at the highest dose
(107 p.f.u). In contrast, large pustular lesions formed on almost all animals infected with
thewt and revertant strains at 107 p.f.u. The lesions for the CBP-knock-out virus resolved
approximately 5–6 days p.i, at a dose of 107 pfu whereas in animals infected with the wt
and revertants at this dose, lesions began to resolve at approximately 10 days p.i. Few
pustules developed at the lowest dose of 103 p.f.u. for all viruses. Immunohistochemistry
of biopsy skin-tissue from pustules showed that the CBP-knockout virus replicated in all
animals at the highest dose and was localized to the skin epithelium while haematoxylin
and eosin staining showed histological features of the CBP-knockout virus typical of the
parent virus with acanthosis, elongated rete ridges and orthokeratotic hyperkeratosis.
MHC-II immunohistochemistry analysis for monocytes and dendritic cells showed greater
staining within the papillary dermis of the CBP-knock-out virus compared with the
revertant viruses, however this was not the case with the wt where staining was similar.
Our results show that the CBP gene encodes a secreted immunodulator that has a critical
role in virulence and pathogenesis.
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INTRODUCTION
Orf is a debilitating skin disease of sheep and goats and is
transmissible to man (Fleming et al., 2015). Orf is also known
as contagious ecthyma, pustular dermatitis, or scabby mouth
and is caused by the parapoxvirus orf virus (ORFV) (Haig,
2006). Orf is an economic and welfare problem in sheep and
goat producing countries world-wide (Haig, 2006). The disease
around the mouth of lambs is associated with poor growth and
can become fatal when secondary infections occur (Fleming et al.,
2015). The disease is usually benign, with lesions that progress
through a papular stage to form pustules within a few days.
These rupture giving rise to ulcers and subsequently a thick
and overlying crust that is shed within 4–6 weeks (Fleming and
Mercer, 2007).
The vaccine against orf is live unattenuated virus that only
produces short-term immunity (Haig and McInnes, 2002).
ORFV usually infects the host through breaks and abrasions
to the skin and replicates in regenerating keratinocytes
(McKeever et al., 1988). Keratinocytes constitute approximately
90% of the cells within the epidermis and are recognized
as immune sentinels within skin (Debenedictis et al., 2001;
Nestle et al., 2009). They express a wide range of Toll-like
receptors and other sensory molecules that allow these cells
to respond rapidly to infection by producing proinflammatory
cytokines and chemokines that results in the recruitment of
immune cells from the underlying dermis and blood during
infection.
Genetic analyses have revealed a number of viral encoded
factors that may explain its ability to establish infection within
the specific immune environment of the skin and its ability
to reinfect its host (Fleming et al., 2015). Several secreted
immunomodulators have been described and these include a
vascular endothelial growth factor (Lyttle et al., 1994; Wise et al.,
1999; Savory et al., 2000), a factor that binds IL-2 and GM-CSF
(Deane et al., 2000), an IL-10-like molecule (Fleming et al., 1997)
and a chemokine binding protein (CBP) (Seet et al., 2003; Lateef
et al., 2009, 2010; Counago et al., 2015).
Chemokines are a large family of secreted chemotactic
proteins that activate and regulate inflammation induced
leukocyte recruitment to sites of infection as well as homeostatic
migration of leukocytes through lymphoid organs (Baggiolini,
1998; Cyster, 1999). Members of the family are classified as
CC, CXC, CX3C, and C according to the spatial arrangement
of cysteine residues within the N-terminus of the molecule. In
general CC chemokines are chemoattractants for monocytes
(Uguccioni et al., 1995) whereas CXC chemokines are
chemoattractants for lymphocytes, NK cells, neutrophils
and B cells (Huang et al., 2001). Chemokines are highly
conserved across mammalian species. Leukocytes are recruited
to sites of inflammation by interaction with chemokine gradients
that form by attachment to the extracellular matrix through
glycosaminoglycan binding domains (Yu et al., 2005). The
predominant chemokines produced during damage and
inflammation of epithelial tissues are CCL2 (MCP-1), CCL3
(MIP-1a), and CCL5 (RANTES) (Kopydlowski et al., 1999;
Wetzler et al., 2000).
Previous studies have revealed that the ORFV CBP is related
to the poxvirus type II CC-chemokine binding proteins (CBP-II)
produced by the Orthopoxvirus and Leporipoxvirus genera (Seet
et al., 2003). Although ORFV CBP displays low sequence identity
to other poxvirus CBPs (<17%) it shares regions of identity and
similarity across its entire sequence. The ORFV CBPencoded by
strain NZ2 has been extensively characterized and is functionally
similar to the CBP-II proteins in its ability to bind many
human inflammatory and constitutive CC-chemokines with high
affinity but also binds XCL1 (lymphotactin) and several CXCL
chemokines (Seet et al., 2003; Lateef et al., 2009, 2010; Counago
et al., 2015). However, the significance of ORFV CBP during
infection of its natural host has yet to be examined.
We hypothesized that the ORFV CBP disrupts chemokine
gradients within the skin tissue of its host during infection and
thereby sets up a blockade to inhibit the recruitment of leukocytes
to the infected site. For these studies we used ORFV strain
NZ7. The NZ7 strain induces large pustular lesions in sheep
and has been used to characterize other ORFV virulence factors
(Fleming et al., 2007; Wise et al., 2007). We firstly characterized
the chemokine binding properties of the purified CBP protein
encoded by ORFV strain NZ7 (CBPNZ7) by ELISA and its effects
on monocyte migration in response to specific chemokines in
a chemotaxis assay and inflammatory cell trafficking using a
murine skin inflammation model. To examine the in vivo effects
of this factor on pathogenesis and host response we constructed
a knock-out recombinant in which the CBP gene was deleted.
Infection studies were carried out in sheep using the recombinant
virus and the clinical pathology and host response compared with
the parent strain.
MATERIALS AND METHODS
Virus and Cells
The ORFVNZ7 strain (Robinson et al., 1987) was propagated in
primary lamb testis (LT) cells as described previously (Robinson
et al., 1982). LT cells were maintained in minimum essential
medium (MEM) (GIBCO, Invitrogen) and supplemented with
FBS at 10% for growth and 5% for culture maintenance. LT cells
were supplemented with PKS solution [kanamycin, (Roche Life
Science); streptomycin. penicillin (Gibco)]. Cells were incubated
at 37◦C in a humidified 7% CO2 atmosphere.
Expression and Purification of CBP
The accession numbers for ORFV strain NZ2 CBP and ORFV
strain NZ7 CBP are CAD99366 and AY453066 respectively.
The coding region of the CBP gene from ORFV strain
NZ7 was amplified by PCR from the Hind-III-E fragment
(Robinson et al., 1987). The primers used for amplification
were N.term 5′-cgcggatccgccaccatgaaggcggtgttgttgct and C.term
5′-cgcggatccttacttgtcatcgtcgtccttgtagtcatggccagggttgaggttaa and
were based on the 5′ and 3′ ends of the CBP coding region,
respectively. Each primer possessed a BamHI site to allow
cloning into the plasmid pAPEX-3 (a gift from Clare McFarlane,
Walter and Eliza Hall, Institute, Melbourne). This cloning
step incorporated a Kozak sequence and FLAG sequence at
the 5′ and 3′ ends respectively, of the coding sequence. The
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plasmid pAPEX-3 contains a simian virus 40 promoter sequence,
transcription termination sequence, and a gene for hygromycin
resistance. The protein was expressed in HEK293 cells and
purified by affinity chromatography with M2 affinity gel by
methods described previously (Seet et al., 2003; Lateef et al.,
2009).
Binding Analysis of CBP Activity by ELISA
Chemokine binding activity was measured indirectly by the
ability of the CBP protein to interfere with the detection of
the chemokines by specific ELISA (Deane et al., 2009; Counago
et al., 2015; Lee et al., 2015). CCL2 OPTI EIA ELISA kits
(BD Biosciences, Franklin Lakes, NJ, and CCL3, CCL5, CCL19,
and CXCL2 DuoSet ELISA Development kits (R&D Systems
Inc, Minneapolis, MN) were used in accordance with the
manufacturer’s instructions. Detailed methods for the ELISA
have been described recently (Lee et al., 2015). Briefly MaxiSorp
96-well immunoplates (Nalgene Nunc) were coated with capture
antibody. In non-absorbent 96-well plates murine chemokines
CCL2, CCL3, CCL5, CCL19, and CXCL2 were mixed with
increasing amounts of CBP diluted in PBS (Lee et al., 2015).
The chemokine/CBP mixes were incubated for 45 min at 37◦C
and then transferred with chemokine standards to the coated
plates for a further 15min incubation at 37◦C. The plates
were washed with PBS/0.005% Tween-20, then incubated for
1 h at room temperature with biotinylated detection antibody
and streptavidin-conjugated horseradish-peroxidase. After a
final wash, captured chemokine was detected with 3,3′,5,5′-
tetramethylbenzidine (BD Biosciences), and the absorbance
measured at 450 nm.
Murine Skin Inflammation Model
The mouse experiments described in this study were approved
by the University of Otago Animal Ethics Committee. Specific
Pathogen Free C57BL/6 mice and enhanced green fluorescent
protein (eGFP) transgenic C57BL/6 mice were obtained from the
University of Otago Animal Facility and used with institutional
ethical approval. Monocyte and DC recruitment from the
blood was assessed using adoptive transfer of eGFP bone
marrow transgenic cells into sex-matched 6–8 week old C57BL/6
recipients as described previously (Lateef et al., 2009, 2010).
Bonemarrow cells were collected from eGFP transgenic C57BL/6
donor mice and resuspended in DPBS (without FCS), and 3
× 107 cells were administered to each recipient in a 200 ul
volume in the tail vein. Twenty-four hours later, inflammation
was induced in the skin by lipopolysaccharide [LPS, (Eschericia
coli derived, Sigma)] intradermal injection. The optimal levels
of LPS to inject into the dermis of the shaved abdomen of
C57BL/6 mice and the time at which maximal monocyte and
DC recruitment was evident, has been described previously
(Lateef et al., 2009, 2010). Briefly, Evans blue dye (2 µl of 1%
solution) was mixed in each sample (total volume 20 µl) to
visualize the rate of diffusion of injected material. A day later
animals were euthanized and the skin around the intradermal
injection site was excised and weighed prior to incubating in
collagenase dispase (Roche Diagnostics) for 3 h. The isolated
cells were counted using a haemocytometer and stained for
cell surface markers CD11b (allophycocyanin-conjugated rat
anti-mouse integrin/CD11b, clone M1/70, isotype IgG2b; BD
Biosciences) and Gr-1 (anti-Gr-1 allophycocyanin-conjugated,
clone RB6-8C5, isotype IgG2b; R&D Systems) for monocytes or
CD11c (allophycocyanin-conjugated clone HL3, isotype IgG1;
BD Pharmingen) and MHC-II (rat anti-mouse I-A/I-E PE-
conjugated from clone M5 (BD Pharmingen) at 4◦C on ice for
2 h. Isotype control was IgG2b) for DC. Flow cytometric analysis
was performed using a FACSCalibur (Becton Dickinson). All
flow cytometric data were analyzed using CellQuest and FlowJo
softwares. All samples were analyzed using flow cytometry counts
of 10,000 events and were normalized to haemocytometer counts
and weight of individual skin biopsies.
Construction of Recombinant ORFV
The CBP knock-out ORFV was made by methods described
previously (Savory et al., 2000; Fleming et al., 2007). The CBP
gene is located within the restriction endonuclease fragment
Hind-III-E of ORFVNZ7 (Seet et al., 2003) GenBank accession No
AY453066. A fragment that spans 500 bp immediately upstream
of the CBP coding region (left arm), was PCR amplified and
cloned into the Hind-III and EcoRI restriction sites of pSP70
to generate pSP70/left arm. A fragment which spans 556 bp
downstream of the CBP coding region and which includes 18 bp
of the CBP gene (right arm), was PCR amplified and cloned into
the vector pSP70/left arm at the EcoRI and BgI-II restriction sites.
Finally the Eschericia coli gene (lacZ), placed under the control of
an ORFV late promoter PF1 (Fleming et al., 1993), was cloned
as a reporter gene into an EcoRI site located between the left
and right arms. The construct was designed to delete 870 nts
from the coding sequence of the CBP gene and to replace this
sequence with ß-galactosidase. The final plasmid construct was
called pCBPnz7-1. The recombinant CBP knock-out (CBP-ko)
virus was generated using a procedure adapted from standard
protocols used in the generation of vaccinia virus recombinants
(Mackett et al., 1984) and methods described previously (Savory
et al., 2000). Putative recombinant plaques were identified 4–
5 days after infection by their blue plaque phenotype in the
presence of 5-bromo-4-chloro-3-indoyl B-D galactopyranoside
(X-Gal).
To construct the CBP revertant, a 1398 bp fragment spanning
500 bp upstream of the CBP coding sequence and which
included the CBP coding sequence and transcription termination
sequence T5NT, was PCR amplified and cloned into the
Hind-III and Kpn-I restriction sites of pSP70 (left arm). In
a further construct to produce a CBP-FLAG fusion protein,
the FLAG sequence was incorporated at the C-terminus of
the CBP coding sequence, that is a FLAG sequence was also
incorporated into a second primer to make the left arm by
amplification as described above. A fragment which spans 556
bp downstream of the CBP coding region and which includes
18 bp of the CBP gene (right arm used to make the knock-
out construct), was cloned into the vector pSP70/left arm at
the EcoRI and BgI-II restriction sites. The reporter gene ß-
glucuronidase (GUS) running off an early/late promoter was
then inserted into the KpnI and EcoRI site, that is between
the left and right arms of the construct. This placed the GUS
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gene downstream of CBP in an intergenic region in the ORFV-
CBP revertant. In addition an early transcription termination
sequence, TTTTTCT, was engineered immediately downstream
of the GUS gene. The final plasmid construct was called pCBP-
rev. The recombinant virus was generated from the ORFV CBP-
ko recombinant by methods described above. Putative ORFV-
CBP revertant plaques were identified by their blue plaque
phenotype in the presence of 5-bromo-4-chloro-3-indolyl B-D-
glucuronide cyclohexylammonium salt and lack of blue color
in the presence of X-gal. The revertant virus was named CBP-
rev. A second revertant was made that incorporated a FLAG
sequence at the C-terminus of CBP and named CBPFLAG-
rev. Characterization of the genomic DNA isolated from the
recombinants was carried out by restriction endonuclease and
PCR analysis by methods described previously (Tan et al.,
2009).
Northern Blotting
To analyse mRNA from virus infected cells by Northern
blotting, total RNA was isolated by methods described previously
(Fleming et al., 1991, 1993). Briefly lamb testis cells (LT),
pretreated with cycloheximide (100µg/ml), were infected with
virus at an MOI of 30 pfu/cell and incubated for 6 h. Total
RNA was isolated from cells using an RNeasy (Quiagen)
purification kit following the manufacture’s instructions. RNA
was stored in 2.5 vol. ethanol, 0.05 vol. 5M NaCl at
−70◦C. RNAs were electrophoresed in denaturing agarose-
formaldehyle gels, blotted onto nitrocellulose membranes and
hybridized with a nick-translated CBP-specific 32P-labeled
dsDNA probe. The size of mRNA was determined using a
BRL RNA ladder. Autoradiography was performed for 72 h at
−70◦C.
SDS-PAGE and Immunoblotting
Affinity purified CBP-FLAG from LT cells infected with
recombinant virus was diluted in SDS-PAGE sample
buffer containing 5% 2-mercaptoethanol, boiled and
then resolved by SDS-PAGE (Laemmli, 1970). Proteins
were transferred to nitrocellulose and reacted with
anti-FLAG Bio-M2 antibody as described previously
(Achen et al., 1998). Blots were developed using a Super
Signal West Pico Chemiluminescence (Perbio) ECL kit
(Perbio).
Infection of Sheep
All animal experiments described in this study were approved by
the University of Otago Animal Ethics Committee. The animals
were housed in a PC2 containment facility at AgResearch,
Invermay, Otago. Twenty-four ORFV sero-negative merino-
cross lambs (ewes) were randomly divided into four groups of
six and inoculated on the wool-free region of the inner hind
legs. Group 1 was infected with wt virus, group 2 with CBP-ko,
group 3 with CBP-rev virus and group 4 with the CBPFLAG- rev
virus. Four lines of scarification approximately 5 cm in length
were made on the epidermis of each of the hind legs and
infected by topical application of 100µl of PBS containing 107,
105 and 103 p.f.u virus or PBS only (no virus control). Virus-
induced lesions were photographed daily over a 3 week period
and the clinical scores determined. Sheep were examined for
erythema, papule and pustule formation and firmly attached
scab associated with the scarified/infected areas of the skin. The
clinical score was determined by counting the discrete round
raised papules with a creamy appearance that formed on the
skin surface along the lines of scarification using magnified
photographic images and the width of the lesion (1–10mm)
FIGURE 1 | CBPNZ7 is a broad-spectrum chemokine binding protein. The chemokines shown were incubated with increasing amounts of either chemokine
binding protein ORFV strain NZ7 (CBPNZ7) or CBPNZ2. Unbound chemokine was then detected using a capture ELISA. The results are presented as the total
chemokine detected. High levels of chemokine indicate no interference in the detection of the chemokine (no chemokine binding) where as low levels of chemokine
indicates interference with detection (positive chemokine binding).
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that formed when papules coalesced (days 5–7). Clinical scores
ranged from 1 to 25. Once the papules/lesions lost their creamy
appearance, that is were in the process of forming scab, the
clinical score was recorded as zero. The clinical scores for all
animals at all-time points were scored by two researches. Punch
biopsies (5mm) were taken at days 4, 6, and 8 from the right leg.
Blood was obtained from the jugular vein of each animal before
infection and then at 13 and 18 days pi when all animals were
euthanized.
Detection of Anti-ORFV Antibodies by
ELISA
Antibodies produced against ORFV antigen and ORFV-075
scaffold protein were analyzed in sheep serum by ELISA. ORFV
antigen was prepared from ORFV-infected LT cells as described
previously (Tan et al., 2012). The expression and purification of
theORFV-075 protein has been described previously (Hyun et al.,
2007). Detailed methods describing the detection of anti-ORFV
antibodies from sheep serum have been described (Bowden et al.,
FIGURE 2 | CBPNZ7 inhibits LPS-induced recruitment of inflammatory monocytes and dendritic cells (DC) into skin. Bone marrow cells from eGFP donor
mice were transfused intravenously into recipient mice 24 h before intradermal injection of LPS (1µg per site) with and without CBPNZ7. In addition each mouse
received injections of CBP only and PBS for a total of four injections per mouse (each mouse within the group received LPS only, LPS + CBP, CBP only, PBS only and
n = 3 animals per group for one experiment). Twenty-four hour later, the recruitment of eGFP/Gr1+/CD11b+ cells and eGFP/CD11c+/MHCII+ cells into the skin were
analyzed. The bar represents the mean ± SD of 3 combined experiments (biological replicates) where n = 9 mice. Asterisks indicate results that are significantly
different (p < 0.01; paired Students t-test).
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2009; Tan et al., 2012). Anti-ORFV antibodies were detected by
coating 96-well Maxisorp Nunc imuno plates (Nunc) with 0.5 ug
ORFV antigen per well and ORFV-075 with 10 ug/well. For pre-
infection control (day 0), serum samples were assayed against
specific antigen and no antigen and for post-infection control,
samples were assayed against no antigen. Following overnight
incubation at R/T washing and blocking with 5% (w/v) skimmed
milk in PBS-T, 100µl of sera were applied to the wells. Sheep
sera were diluted 1/400. The plates were incubated for 1.5 h at
R/T followed by 3 washes with PBS-T. Serum antibodies were
detected using 100µl of 1:2000 rabbit anti-sheep Ig-HRP. The
plates were incubated for 1.5 h at R/T and washed in PBS-T prior
to detection. One hundred microliter of o-phenylenediamine
dihydrochloride (OPD) substrate solution (Sigma) was applied to
all wells and color allowed to develop in the dark. The reactions
were read at OD490 nm.
Sheep Skin Histology: Haematoxylin and
Eosin Staining and Immunofluorescence
Skin biopsies (5 mm) from sheep were treated with zinc salt
fixative (González et al., 2001) and embedded in paraffin wax for
cellular analysis. Sections were cut at 4µm, mounted on glass
slides and then dried at 60◦C for 1 h. Sections were then re-
fixed in zinc salts for 7 days at room temperature before bench
drying. Adjacent sections were stained with either haematoxylin
and eosin (H & E), or anti-MHC II.
Haematoxylin and Eosin Staining
H & E staining has been described previously (Anderson et al.,
2001).
MHC-II by Immunofluorescence
For immunofluorescent staining of MHC-II, slides were dried
O/N at 37◦C tissue sections were de-paraffinated and rehydrated
with xylene for 15 min, 100% ethanol for 30 s, 100% 1-propanol
for 30 sec, 90% 1-propanol for 30 s, and 70% 1-propanol for
30 sec. To rehydrate, sections were soaked in 0.85% NaCl for
5min, followed by TBS for 30min. For antigen retrieval, slides
were immersed in 37◦C TBS for 20min, then room temperature
TBS for 20min. Sections were blocked in 10% sheep serum/TBS
for 30 min at room temperature in a humidified box. Sections
were then incubated with 0.02 mg/ml mouse anti-ovine MHC
Class II:FITC (Serotec, MCA2228F) in 10mg/ml BSA/0.05%
Triton X/TBS, and incubated O/N at 4◦C. DAPI 1 was added
for 30min before sections were washed three times in 0.05%
Tween20 TBS, then rinsed in TBS only. Sections were mounted
with SlowFade Gold Antifade Mountant (Invitrogen S36936).
The stained sections were viewed by fluorescent microscopy
using an Olympus BX51 and then photographed using an
Olympus digital camera. Cell counts were performed using Image
J Fiji software by subtracting background, increasing contrast,
creating a RGB stack, selecting either the epidermis, or the
papillary dermis, determined by the smooth collagen and elastic
FIGURE 3 | ORFV lesion clinical scores of sheep infected with wt and recombinant viruses. Infection with a dose of 107 p.f.u. virus of each wt, CBP
knock-out virus (ko) CBP revertant virus and CBPFLAG revertant virus. There were 6 animals per group and the clinical scores are shown for each animal from day 3 to
day 18 p.i. at which time the lesions in all animals had resolved (detached scab).
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fibers then measuring percentage area that stained positive in the
green field.
Detection of ORFV Antigen by Immunofluorescence
For immunohistochemical staining of the ORFV F1L envelope
protein, tissue sections were de-paraffinated and rehydrated as
described above. Sections were then blocked in TBS+ 5% FCS for
30 min and reacted with anti-ORFV F1L monoclonal antibody
(8D7) (Housawi et al., 1998; a gift from Peter Nettleton, Moredun
Research Institute UK) diluted 1/2000 in 1% TBS /BSA/0.01%
tritonX and incubated O/N at 4◦C. Sections were then washed
in 1% TBS and incubated with goat anti-mouse alexa 594 (1/400
dilution) and DAPI (1:200 dilution) for 1.5 h in the dark. The
stained sections were viewed by light microscopy or fluorescent
microscopy.
Statistical Analysis
The mouse skin inflammation data was analyzed by paired
Student’s t-test and the statistical analyses were performed
using the MegaStat suite under Excel. The sheep clinical score
FIGURE 4 | The mean ORFV lesion clinical scores of sheep infected with wt and recombinant viruses. The mean clinical score for each group infected with
a dose of 107 p.f.u. is shown. Asterisks indicate where the CBP-ko virus is significantly different to wt and revertants (p < 0.05, Mann-Whitney test).
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data for ORFV lesions was analyzed using the Mann-Whitney
test (http://math.usask.ca/∼laverty/S245/Tables/wmw.pdf). The
sheep MHC-II immunofluorescence data was analyzed by
One-Way ANOVA with means comparison using Sidak’s test
(GraphPad Prism 6).
RESULTS
CBPNZ7 Shows Broad-Spectrum
Chemokine Binding Specificity
The CBP gene shows surprising variability within the ORFV
species with the strain NZ7 CBP showing only 78% identity to
the strain NZ2 CBP at the amino acid level (Seet et al., 2003).
These differences are partly due to three insertions in CBPNZ7
making the gene 27 nts longer than CBPNZ2 with a predicted
polypeptide of 32.193 kDa compared with 31.182 kDa. It was
therefore necessary to first examine the in vitro properties of
CBPNZ7 and compare these with the published data of CBPNZ2.
To examine the chemokine binding properties of CBPNZ7, the
CBPNZ7 gene was cloned into the pAPEX eukaryotic expression
vector and expressed as a C-terminal FLAG tagged fusion
protein following transfection of HEK293 cells. The protein
was affinity purified using anti-FLAG beads and tested for its
ability to bind murine chemokines using an ELISA assay. The
chemokine binding specificity of CBPNZ7 was compared with
CBPNZ2 over a broad range of chemokines that are produced
during inflammation in skin and the constitutive chemokine
CCL19. The ELISA carried out is an indirect assay and measures
free chemokine (not in complex with CBP) following CBP
incubation with chemokine. Therefore, the stronger the binding
the less free chemokine that remains. The assay showed that
CBPNZ7 bound the murine inflammatory chemokines CCL2,
CCL3, CCL5, and CXCL2 (Figure 1). It also bound the murine
constitutive chemokine CCL19. Overall its binding specificities
were similar to CBPNZ2 over the range of chemokines tested
with stronger binding to CCL3 and CCL19, that is, there was
less free chemokine available at a concentration of 37.5 ng/ml for
CBPNZ7.
FIGURE 5 | Lesions of ORFV infected sheep at day 6 p.i., dose 107 p.f.u. virus.
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FIGURE 6 | ORFV lesion clinical scores of sheep from infection with
three different doses of virus (103, 105, and a 107 p.f.u.) of wt, CBP-ko,
CBP-revertant and CBPFLAG- revertant at day 6 p.i. There were 6 animals
per group and the clinical scores are shown for each animal. The bar
represents the mean clinical score for each group and asterisks indicate where
the CBP-ko virus is significantly different to wt and revertants (p < 0.05,
Mann-Whitney test).
CBPNZ7 Inhibits Inflammatory Cell
Recruitment in a Mouse Skin Inflammation
Model
The injection of small amounts of LPS in mouse skin results
in highly localized inflammation through the upregulation of
inflammatory chemokines that results in the recruitment of
monocytes and DC to the site (Haberstroh et al., 2002; Charo
and Ransohoff, 2006). The ability of CBPNZ7 to inhibit monocyte
and DC recruitment to inflamed skin was tested. Optimization
of the mouse skin inflammation model and analysis of the
inflammatory cell infiltrate has been described previously (Lateef
et al., 2009, 2010). We tested whether CBPNZ7 could impair
recruitment of blood-derived monocytes and DC to the skin.
Bone marrow cells from eGFP transgenic C57BL/6 donor mice
were administered to C57BL/6 recipientmice. Twenty-four hours
later animals were co-injected with 1µg LPS with or without
various amounts of CBPNZ7 (total volume 20 ul) into the dermis
of the shaved abdomen of the recipients. Twenty-four hours later
mice were euthanized and the skin around the injection site
excised and cells isolated and stained. The number of monocytes
and DC in skin was determined by flow cytometric analysis. The
results showed that CBPNZ7 potently inhibited the recruitment of
blood derived eGFP monocytes and eGFP DC at 1 and 100 ng of
CBPNZ7 (P < 0.01, Students t-test for paired samples) with the
greatest effect seen at 100 ng CBPNZ7 (Figure 2).
Replication of the CBP-Knock-Out Virus
and Revertants in Cell Culture and
Expression of CBP from the
CBPFLAG-Revertant Virus
In order to study the effects of the ORFV CBP gene in the
context of a viral infection in its natural a host, a CBP knock-
out recombinant virus was made by homologous recombination.
To construct the revertant viruses, the CBP gene was reinserted
into the CBP knock-out virus. The growth of the recombinant
viruses was compared with the parent virus in LT cells at 30 h post
infection. All viruses exhibited similar growth and importantly
the deletion of the CBP gene did not compromise its ability to
replicate in cell culture (Figure S1). In addition transcription of
CBP mRNA of the revertant viruses and the knock-out virus
were compared with the parent virus by Northern blotting. The
results showed that CBP mRNA could be detected in LT cells
infected with the wt virus and the CBP revertant recombinants
but not from the CBP knock-out virus (Figure S2). Expression
of CBP-FLAG from the ORFV-CBP-FLAG-revertant was also
examined by western blotting of virus-infected cells and the
results showed that expression of CBP-FLAG could be detected
for this recombinant (Figure S3).
Infection of Sheep With CBP Knock-Out
ORFV Showed Reduced Pathogenesis
Experimental infection of sheep with wt ORFVNZ7 by
scarification of the skin generally results in discrete papules
and pustules that form along the scratch line. As the lesions
develop the pustules coalesce to form a continuous pustular
lesion. In this study, groups of six animals were infected with
either wt, CBP ko virus, CBP-rev virus or the CBPFLAG-rev
virus at 3 doses; 107, 105, and 103 p.f.u. virus and PBS (mock
infected control). Infected skin was photographed to provide a
record of the clinical pathology from which the clinical score
could be determined from the number, appearance and size of
papules and pustules that developed along the scratch line. The
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FIGURE 7 | Histological sections from punch biopsies of virus-infected animals were stained by H & E or by immunohistochemical staining for the
ORFV envelope protein F1L. (A) Day 4 p.i. at a dose of 107 p.f.u. wt virus. Adjacent sections were stained by H & E and ORFV F1L antigen. In addition ant-FIL
staining was performed for the mock-infected (PBS) control. Staining for ORFV infected tissue is seen localized to the epidermis and in epidermal cells of the hair
follicle. (B) Typical F1L staining in animals infected with the CBP knock-out virus at a dose of 107 p.f.u. virus at day 6 p.i. The biopsies were taken from
papules/pustules that had developed along the virus-inoculated scratch line. The images were taken at 4X magnification.
clinical score for each animal infected with a dose of 107 pfu
virus is shown in Figure 3 over the course of the infection and
the mean clinical scores for each group during the course of
infection is shown in Figure 4. By day 3 p.i., 2 animals infected
with the CBP ko virus showed early development of papules
and pustules that were not seen at this time in animals infected
with either the wt virus or CBP revertant viruses. By day 4 p.i.,
4 of the animals in the ko group had developed small pustules.
Sheep infected with wt and the CBP revertants developed lesions
typically observed for the NZ7 strain of ORFV and papules and
pustules were visible by day 4 p.i. By day 5 p.i., large pustular
lesions had developed in the wt and CBP revertant groups and
the clinical scores were significantly greater than sheep infected
with the CBP ko virus (P < 0.05). In contrast, lesions in the
CBP knockout group were beginning to resolve by day 5 p.i.
By day 6 p.i., lesions in the wt and CBP revertants groups had
reached their maximum clinical pathology (Figures 3–5) and
there was little difference in the mean clinical scores at this
time; wt 18.33 (SE 2.99), CBP rev 20.33 (SE 2.26), CBPFLAG
rev 19.50 (SE 2.80). In contrast, lesions had resolved in 3 of
the animals in the CBP knock-out group by this time and the
group had a mean clinical score of 4.83 (SE 2.46). The clinical
scores for the wt and CBP revertant groups were significantly
different to the CBP knockout group (P < 0.02) at day 6 p.i.
By day 7 p.i., lesions had resolved in all but 2 animals in the
CBP knock-out group. By day 8 p.i. the clinical pathology in
almost all animals was less apparent and lesions were beginning
to form scabs. By day 10 p.i., scabs had formed on all animals
except for 3 in the CBP revertant group. By day 18 p.i., lesions
had resolved on all animals and scab had detached. Throughout
the course of the experiment, the clinical scores for the wt
and revertant groups were not significantly different to each
other.
At an infectious dose of 105 virus per inoculum, the trend
in clinical pathology at day 6 was similar to that for animals
infected with a virus dose of 107 (Figure 6). The mean clinical
scores for the wt group was 6.12 (SE 2.18) and for the CBP
rev and CBPFLAG rev groups 4.50 (SE 2.29) and 5.33 (SE 1.96)
respectively. In contrast the clinical score for the CBP ko virus
group was 0.50 (SE 0.50). The clinical scores for the wt and the
CBP revertant groups were significantly different to the CBP
knock-out group (P < 0.05). At 105 virus per inoculum the
lesions resolved in less time than for the 107 dose administered.
At a dose of 103 virus per inoculum few animals developed
lesions and these were only seen in the wt and revertant groups
(Figure 6).
In summary the deletion of the CBP gene had a marked effect
on the clinical pathology. Within the first 3 days many typical
papules formed in the CBP ko group at the highest dose, however,
surprisingly few of these papules progressed further to form
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FIGURE 8 | Histopathology of ORFV infected skin tissue. H & E stained sections from biopsy tissue at day 4 p.i., dose 107 of p.f.u. virus. (A) mock-infected
(PBS) skin (B) CBPFLAG -revertant showing histological features of infected tissue (C,D) histological features of CBP-knockout virus (E) CBP-revertant virus infected
tissue showing parakeratosis and necrotic keratinocytes (F) wt infected tissue showing hyperkeratosis. The images were taken at 40X magnification.
pustules and in fact diminished with time. There was only one
sheep infected with a CBP deletion mutant that showed signs of
pustular development by day 6 p.i. In contrast all animals infected
with either wt virus or the CBP revertants developed pustules
by this time. In many animals the number and size of pustules
infected with the revertants were comparable with the wt and
resolved in approximately the same time.
Immunohistochemical Analysis Showed
that the CBP Knock-Out Virus Replicated
in Sheep
In order to establish whether or not the CBP-knock-out virus
replicated in sheep-skin, biopsy tissue sections were stained
for the ORFV F1L major immunodominant antigen that is
associated with the virus envelope. F1L antigen staining is clearly
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FIGURE 9 | MHC-II staining of ORFV infected skin tissue and mock infected. Biopsy tissue day 4 p.i., dose 107 p.f.u. virus. Adjacent sections for H & E (a) and
MHC-II staining (b) are shown: (1) mock infected (PBS), (2) wt, (3) CBP-knock-out virus, (4) CBP revertant virus. MHC-II positive cells (green); cell nuclei (DAPI) (blue);
non-specific staining of red blood cells (red). The images were taken at 40X magnification.
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FIGURE 10 | MHC-II staining in the epidermis and papillary dermis. The percent area for MHC-II staining was determined using Image J Fiji. Biopsy tissue day 4
p.i., dose 107 p.f.u. virus and for mock infected (PBS). The data was analyzed by One Way ANOVA plus Sidoks test where N = 6 for wt, CBP-knockout (KO),
CBP-FLAG revertant, and CBP revertant, that is one biopsy taken from each infected animal. N = 22 for mock infected (biopsies taken from animals across all 4
groups).
seen within the epidermal layer for the wt virus (day 4 p.i.)
where contiguous sections were stained by H & E and for
F1L (Figure 7A). There was no staining detected for the mock-
infected control (Figure 7A). In the case of the CBP-knock-
out virus, biopsies were taken where there was evidence of a
raised papule or pustule. F1L antigen staining clearly showed that
the CBP-knock-out virus established productive infection in all
animals within this group. Figure 7B shows examples of typical
staining for 3 of the animals in the CBP ko virus at day 6 p.i.
Histology Analysis of CBP-Knock
Virus-Infected Skin Tissue Revealed
Changes Typical of The wt Virus
ORFV infected tissue was analyzed by H & E staining at day
4 p.i. As described above, biopsies for the CBP-ko group were
taken from the skin where there was evidence of a raised
papule or pustule. Animals infected with the CBP-ko virus
showed marked acanthosis (thickening of the stratum basal and
stratum spinosum), elongated rete ridges and orthokeratotic
hyperkeratosis (thickening of stratum corneum) typical of the wt
virus (Figure 8). The same histological features were also seen for
the revertant viruses. This was not seen for the mock-infected
control group. All infected animals had increased (moderate
to extreme) inflammatory infiltrate, most notable within the
papillary dermis, but also entering the epidermis. In all virus-
infected groups hypergranulosis (thickened cornified layer) and
parakeratosis (cell nuclei present in the cornified layer) were
present (Figure 8). Again these features were not seen in the
mock-infected group.
The H & E staining revealed that the inflammatory cell
infiltrate was similar but variable for wt, CBP-ko and CBP
revertant viruses during the early stages of infection (day 4) when
clinical signs of infection were first becoming apparent. At a dose
of 107 virus per inoculum, the numbers of inflammatory cells
for the wt, CBP-ko and CBP revertants varied from medium
to heavy. At a dose of 105 virus per inoculum, there was a
similar influx of inflammatory cells but again this was variable for
infected animals within groups. In the PBS controls there were
few inflammatory cells seen (Figure 8A).
MHC-II Staining Revealed Differences
between the Virus-Infected Groups
MHC-II staining at day 4 p.i. is shown in Figure 9. The adjacent
sections show that for mock-infected (PBS) tissue there was
very little MHC-II staining either within the papillary dermis or
within the epidermis. For virus-infected tissue however MHC-II
staining increased for all the groups but was variable for virus-
infected animals within groups. All mock infected skin tissue
showed clearly defined and intact nuclei in the dermis by DAPI
staining, however virus infected animals consistently showed
histopathological changes in the nuclei that were not seen in the
mock infected tissue, that is the edges of nuclei for virus infected
skin were not as sharply defined and appeared smeared compared
with mock infected skin tissue (Figure S4).
The quantification of MHC-II staining is shown in Figure 10.
The percent area MHC-II staining in the epidermis for the
CBP-ko virus group was higher compared with the wt virus
group and animals infected with the revertant viruses, however
the percent area staining was only significantly higher for the
CBP-ko virus compared with the CBP-FLAG-rev virus (P =
0.0069). Interestingly the wt and both revertant viruses were not
significantly different to the mock-infected animals whereas the
CBP-knock-out-virus was significantly higher than the mock-
infected control group (P = 0.0479). The percent area MHC-II
staining in the papillary dermis revealed slightly higher staining
for MHC-II for the wt virus compared with the CBP-ko virus,
however the difference was not significant. Interestingly the
percent area staining of MHC-II cell in the papillary dermis
was significantly less for both revertant viruses compared with
the CBP-ko virus and the wt virus (P < 0.01 and P < 0.05
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FIGURE 11 | Serological analysis of anti-ORFV antibodies in infected
sheep. Sheep sera from animals infected with either ORFV wt or
CBP-knock-out virus (ko) or CBP-revertant virus (rev) or CBPFLAG revertant
(rev-F) were tested for antibodies against ORFV antigen (A) or the ORFV
scaffold protein ORFV075 (B) at 0 and 18 days p.i. by ELISA. Shown are the
serum antibody absorbance values for each animal (serum dilution 1/400) and
the mean serum antibody absorbance values for each group. P values
determined by Mann-Whitney test.
respectively). The percent area MHC-II staining in the papillary
dermis for the revertant viruses was again not significantly
different to the mock-infected animals.
A primary Antibody Response was
Detected against the ORFV 075 Scaffold
Protein in Sheep Infected with the CBP
Knock-Out Virus
We were interested to determine whether animals produced
an immune response against antigen produced by the virus
in infected cells by de novo synthesis. ORFV-075 is a scaffold
protein that is produced late in infection but is not incorporated
into the viral particle. Figure 11A shows that all animals had
seroconverted and produced a typical antibody response against
ORFV antigen by day 18 pi. There was no significant difference
in antibody levels between the wt and CBP ko virus (P =
0.061) however there was a significant difference between the
wt and the revertant (P = 0.0465). Detection of antibodies
against ORFV-075 showed that the ORFV-CBP-knock-out virus
had replicated in all infected animals (Figure 11B). A significant
difference was found between the wt and the CBP ko virus in
this case (P = 0.0274) with the wt producing a higher antibody
response. Further there was a significant difference in antibody
levels for the wt compared with the revertant virus (P = 0.0465)
but not between the other groups.
DISCUSSION
We firstly characterized the biological properties of the purified
ORFV-NZ7 CBP protein and then investigated the effects of
deleting the CBP gene from ORFV on replication, virulence,
pathogenesis, and host response. As described above, the CBP
gene shows surprising variability within the ORFV species with
the NZ7 strain showing 78% identity to the NZ2 strain (Seet et al.,
2003). Because of these genetic differences, experiments were
conducted initially to investigate and characterize the biological
properties of the putative CBPNZ7 prior to investigations in sheep
with recombinant virus. Chemokine binding assays showed
that it displayed the equivalent biological properties as CBPNZ2
despite differences in their primary structure. In addition,
CBPNZ7 potently blocked the inflammatory cell infiltrate when
injected intradermally at ng levels in a mouse skin model,
suggesting that it could have a role in pathogenesis.
In the context of ORFV infection of sheep, the deletion of
the CBP gene had a marked effect on the clinical pathology.
Within the first 3 days many typical small papules formed in the
CBP knock-out group, however, surprisingly few of these papules
progressed further to form pustules and in fact diminished with
time. There was only one sheep infected with the CBP-knockout
virus that showed signs of pustular development by day 6 p.i.
There was little evidence in the case of the other animals within
this group that the CBP-knockout virus had established infection.
To demonstrate replication, we were able to detect viral antigen
in tissue by immunofluorescence from biopsies specifically taken
from the few raised papules that were observed in each animal
within this group. Within the papules the histology of the CBP-
knockout virus infected tissue resembled the wt and revertant
viruses with evidence of acanthosis, elongated rete ridges and
hyperkeratosis. Furthermore by day 4 p.i., it was evident that
there was a medium to large inflammatory cell infiltrate in thewt,
CBP-knock-out virus and CBP-revertant virus lesions by H & E
staining.
We investigated the infiltration of immune cells into the
infected site by staining for MHC-II. The percent area staining
for MHC-II suggested that there was greater infiltration of the
papillary dermis in the case of the CBP-knock out virus group
compared with the revertant virus groups but not compared
with the wt group. In addition there was significantly higher
MHC-II staining in the epidermis for the CBP-knock-out virus
compared with the CBP-FLAG revertant virus group. The results
suggest, for the recombinant viruses at least, that secreted CBP
from virus infected cells in the epidermis maybe disrupting
chemokine gradients and reducing immune cells reaching the
site of infection. Its puzzling as to the reason for the higher
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percent area staining for MHC-II for the wt compared with the
revertant viruses, both in the epidermis and papillary dermis,
when the clinical lesions appeared similar. If the secreted CBP is
preventing immune cells reaching the site of infection an inverse
relationship might be predicted between MHC-II staining and
the severity of the clinical lesions. It’s possible that within the first
few days post-infection, the critical cellular immune events that
determine the establishment of infection have occurred. Perhaps
biopsy material taken from the infected area before signs of
viral pathology emerged might have provided insight into such
immune events.
Humoral antibody analysis provided a measure of the
induction of the adaptive responses. The anti-ORFV antigen
levels for the CBP knock-out virus were comparable with the
wt virus and the revertants although there were few outward
signs of clinical infection in the CBP-knockout virus at the
highest dose, apart from papules within the first 3–5 days.
There appeared to be little correlation between the magnitude
of clinical lesions over the course of the experiment and the
serum antibody levels detected at 18 days p.i. It’s possible that
the adaptive responses could have been mobilized more rapidly
in the case of the CBP-knock-out virus where immature DC
trafficking to the skin and migration of mature DC to peripheral
lymph nodes would have been less disrupted than for the intact
virus. The humoral antibody response normally takes about 4–5
days to develop (Janeway et al., 1999) and we did not determine
whether this response was initiated more rapidly in animals
infected with the CBP-knock-out virus compared with the wt or
CBP-revertants.
The only other study in which a poxvirus CBP knock-
out virus has been tested in the context of in vivo infection
is rabbitpox virus (RPV) (Graham et al., 1997). In that case
the virus was injected intradermally. The CBP knock-out RPV
showed an influx of at least two classes of leukocytes at 3 days
post-infection. Influx of CD43-positive lymphocytes (possibly
NK cells), monocyte/macrophages as well as CD43-negative
granulocytes in the knock-out virus. The results suggested that
the expression of the RPV 35 kDa secreted CBP functions
during the early stages of infection to reduce the initial influx
of extravasating leukocytes. Although we suspect that the ORFV
CBP most likely reduced the influx of such cell types identified in
RPV infections, we were not able to establish whether or not the
ORFVCBP influenced leukocyte migration. Overt signs of ORFV
clinical infection are generally not apparent until 3 days p.i. and
it’s possible that the effects of the CBP gene were manifested
before this time.
Our studies clearly showed that the CBP gene is critical in
ORFV pathogenesis and virulence and although ORFV encodes a
number of other secreted anti-inflammatory factors, the deletion
of CBP gene severely attenuated the virus. The secreted CBP
appears to induce its effects early during infection, since there
were few signs of clinical orf in almost all CBP knock-out
virus infected animals. At this time we do not know which
cells or factors were involved in the faster control of the ORFV
CBP-knock-out virus infection. The deletion of the CBP gene
may however be advantageous for recombinant ORFV vaccine
development. Although its deletion severely attenuated the virus,
a primary antibody response typical of the wt virus was observed.
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Figure S1 | Growth of recombinant ORFVs in cell culture. Lamb testis cells
at 5 × 105 were infected with either wt, ORFV-CBP knock-out (CBP-ko), ORFV
CBP revertant (CBP-rev) or ORFV CBPFLAG revertant (CBPFLAG-rev) at an MOI of
0.2, 1 and 5 p.f.u/cell in triplicate. At 30 h p.i. virus was harvested and the virus
levels determined by plaque assay (Balassu and Robinson, 1987). Mean ± SD is
shown.
Figure S2 | Northern blot analysis of total RNA isolated from LT cells
infected with recombinant ORFV. Cells were infected with ORFV in the
presence of cycloheximide (100µg/ml) at an MOI of 30 pfu. RNA was isolated at
6 h post-infection. Hybridisation was performed with a CBP-specific 32P-labeled
DNA probe. Bands indicate mRNA of 900–1000 bp. Cells were either mock
infected or infected with ORFV-CBP-FLAG-revertant,ORFV-CBP-revertant
ORFV-CBP-knockout and ORFV wild type.
Figure S3 | Western blot analysis of CBPexpression by CBPFLAG-revertant
ORFV. LT cells were infected with virus and incubated for 5 days. Both the
supernatant and cell lysate were collected for analysis of CBPFLAG protein.
Protein was enriched by affinity chromatography using α-FLAG-M2 Affinity Gel.
Proteins were detected with anti-FLAG antibody. Lane 1 mock infected, lane 2
CBPFLAG purified protein, lane 3 ORFV-CBPFLAG-revertant (cell lysate), lane 4
ORFV-CBP-revertant (supernatant), lane 5 ORFV-CBPFLAG (supernatant).
Figure S4 | Comparison of DAPI staining in biopsy tissue from sheep
either mock-infected or infected with ORFV CBP-ko at a dose of 107 pfu
at day 4 p.i.
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